NASDAQ:COLL - Collegium Pharmaceutical Stock Price, Forecast & News

Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."

Collegium Pharmaceutical Inc (NASDAQ:COLL) posted its quarterly earnings data on Wednesday, November, 6th. The specialty pharmaceutical company reported ($0.18) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.15) by $0.03. The specialty pharmaceutical company earned $72.94 million during the quarter, compared to analysts' expectations of $74.32 million. Collegium Pharmaceutical had a negative return on equity of 13.14% and a negative net margin of 3.86%. The firm's revenue for the quarter was up 3.9% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.50) EPS. View Collegium Pharmaceutical's Earnings History.

Collegium Pharmaceutical is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Collegium Pharmaceutical.

Collegium Pharmaceutical will be holding an earnings conference call on Thursday, February 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Collegium Pharmaceutical issued an update on its FY 2020 Pre-Market earnings guidance on Friday, February, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $320-340 million, compared to the consensus revenue estimate of $331.36 million.

8 brokerages have issued 12-month price objectives for Collegium Pharmaceutical's shares. Their forecasts range from $22.00 to $43.00. On average, they anticipate Collegium Pharmaceutical's share price to reach $32.29 in the next twelve months. This suggests a possible upside of 34.9% from the stock's current price. View Analyst Price Targets for Collegium Pharmaceutical.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Collegium Pharmaceutical.

Headlines about COLL stock have trended very negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Collegium Pharmaceutical earned a coverage optimism score of -3.6 on InfoTrie's scale. They also assigned news stories about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Collegium Pharmaceutical.

Collegium Pharmaceutical saw a increase in short interest in January. As of January 31st, there was short interest totalling 2,310,000 shares, an increase of 13.2% from the January 15th total of 2,040,000 shares. Based on an average daily trading volume, of 451,400 shares, the short-interest ratio is currently 5.1 days. Currently, 7.9% of the company's stock are short sold. View Collegium Pharmaceutical's Current Options Chain.

Some companies that are related to Collegium Pharmaceutical include Myokardia (MYOK), Allakos (ALLK), Intercept Pharmaceuticals (ICPT), Deciphera Pharmaceuticals (DCPH), PPD (SDGR), Apellis Pharmaceuticals (APLS), ChemoCentryx (CCXI), Taro Pharmaceutical Industries (TARO), Uniqure (QURE), Amicus Therapeutics (FOLD), Insmed (INSM), Arena Pharmaceuticals (ARNA), ArQule (ARQL), Biohaven Pharmaceutical (BHVN) and Karuna Therapeutics (KRTX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include GALAPAGOS NV/S (GLPG), AbbVie (ABBV), NVIDIA (NVDA), Canopy Growth (CGC), Advanced Micro Devices (AMD), Bausch Health Companies (BHC), Celgene (CELG), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT) and Ocular Therapeutix (OCUL).

(COLL) raised $75 million in an IPO on Thursday, May 7th 2015. The company issued 5,800,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

Collegium Pharmaceutical's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Janus Henderson Group PLC (13.43%), Franklin Resources Inc. (5.28%), Renaissance Technologies LLC (3.74%), Rice Hall James & Associates LLC (3.15%), Emerald Advisers LLC (2.33%) and Emerald Mutual Fund Advisers Trust (2.28%). Company insiders that own Collegium Pharmaceutical stock include Alison B Fleming, David Hirsch, Joseph Ciaffoni, Michael Thomas Heffernan, Paul Brannelly and Scott Dreyer. View Institutional Ownership Trends for Collegium Pharmaceutical.

COLL stock was sold by a variety of institutional investors in the last quarter, including Rice Hall James & Associates LLC, Sectoral Asset Management Inc, Massachusetts Financial Services Co. MA, Franklin Resources Inc., Charles Schwab Investment Management Inc., Oxford Asset Management LLP, J. Goldman & Co LP and Bank of America Corp DE. Company insiders that have sold Collegium Pharmaceutical company stock in the last year include David Hirsch, Joseph Ciaffoni, Michael Thomas Heffernan and Scott Dreyer. View Insider Buying and Selling for Collegium Pharmaceutical.

COLL stock was acquired by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Renaissance Technologies LLC, Perceptive Advisors LLC, Perceptive Advisors LLC, Driehaus Capital Management LLC, Janus Henderson Group PLC and Bank of Montreal Can. View Insider Buying and Selling for Collegium Pharmaceutical.

Shares of COLL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of COLL stock can currently be purchased for approximately $23.93.

Collegium Pharmaceutical has a market capitalization of $802.37 million and generates $280.41 million in revenue each year. The specialty pharmaceutical company earns $-39,130,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. Collegium Pharmaceutical employs 266 workers across the globe.View Additional Information About Collegium Pharmaceutical.

The official website for Collegium Pharmaceutical is http://www.collegiumpharma.com/.

Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The specialty pharmaceutical company can be reached via phone at 781-713-3699.